Cart
sales@molnova.com
Perifosine
CAS No. 157716-52-4
Perifosine( KRX-0401 | NSC 639966 | D-21266 | KRX 0401 | KRX0401 | D21266 | D 21266 )
Catalog No. M12254 CAS No. 157716-52-4
A oral bioavailable alkylphospholipid that displays significant antiproliferative activity in vitro and in vivo in several human tumor model; acts as an Akt inhibitor and a PI3K inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 35 | In Stock |
|
| 5MG | 57 | In Stock |
|
| 10MG | 73 | In Stock |
|
| 25MG | 147 | In Stock |
|
| 50MG | 267 | In Stock |
|
| 100MG | 421 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePerifosine
-
NoteResearch use only, not for human use.
-
Brief DescriptionA oral bioavailable alkylphospholipid that displays significant antiproliferative activity in vitro and in vivo in several human tumor model; acts as an Akt inhibitor and a PI3K inhibitor.
-
DescriptionA oral bioavailable alkylphospholipid that displays significant antiproliferative activity in vitro and in vivo in several human tumor model; acts as an Akt inhibitor and a PI3K inhibitor, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway; enhances apoptosis and inhibits the growth of xenografts in nude mice combined with a lysosomal inhibitor.Brain Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsKRX-0401 | NSC 639966 | D-21266 | KRX 0401 | KRX0401 | D21266 | D 21266
-
PathwayPI3K/Akt/mTOR signaling
-
TargetAkt
-
RecptorAkt
-
Research AreaCancer
-
IndicationBrain Cancer
Chemical Information
-
CAS Number157716-52-4
-
Formula Weight461.6584
-
Molecular FormulaC25H52NO4P
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=P(OC1CC[N+](C)(C)CC1)([O-])OCCCCCCCCCCCCCCCCCC
-
Chemical NamePiperidinium, 4-[[hydroxy(octadecyloxy)phosphinyl]oxy]-1,1-dimethyl-, inner salt
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kondapaka SB, et al. Mol Cancer Ther. 2003 Nov;2(11):1093-103.
2. Patel V, et al. Cancer Res. 2002 Mar 1;62(5):1401-9.
3. Becher OJ, et al. Cancer Res. 2010 Mar 15;70(6):2548-57.
molnova catalog
related products
-
PF-04691502
PF-04691502 is an ATP-competitive PI3K(α/β/δ/γ)/mTOR dual inhibitor with Ki of 1.8 nM/2.1 nM/1.6 nM/1.9 nM and 16 nM.
-
BAY-1125976
A potent and highly selective, allosteric AKT1/2 inhibitor with IC50 of 5.2/18 nM at 10 uM ATP.
-
Ipatasertib
Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor.
